19240QAA0

Could not find a ticker for this position, may be a filing error

A clinical-stage biotechnology company in Waltham, Massachusetts, developing precision therapies for genetically defined diseases. Its lead drug candidate, bezuclastinib, targets the KIT D816V mutation that drives systemic mastocytosis, a rare disease marked by abnormal buildup of mast cells. The company took its name in 2020 when Unum Therapeutics combined with a private firm also called Cogent Biosciences — "cogent" meaning clear, logical, and convincing.

1.625% Convertible Senior Notes due 2031

2026 Q12 of 3 quarters

No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.

Derivative Reporters

Investor

Kind

13F reported value

Quantity

Change

Oaktree Capital Management

Note/bond (principal)

$12.54M

10.22M principal

+2.57M (+33.6%)

Major holders (13D/G) →